University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Matthew R. Cooperberg, MD, MPH

Matthew R. Cooperberg, MD, MPH

Associate Professor, Department of Urology, UCSF
Helen Diller Family Chair in Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

Health Services

Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.

Prostate Cancer Risk Assessment and Comparative Effectiveness Research

Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.

Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.

Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.

Survivorship

Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.

Small Renal Masses

In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.

Education

Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy


Professional Experience

  • 2000-01
    Internship in General Surgery (preliminary to Urology), Yale University, New Haven, CT
  • 2001-03
    Research Fellowship in Genitourinary Oncology, University of California, San Francisco, CA
  • 2004-08
    Residency in Urology, University of California, San Francisco, CA
  • 2008-09
    Clinical Fellow, Genitourinary Oncology, University of California, San Francisco, CA
  • 2009-2013
    Assistant Professor, Department of Urology, University of California, San Francisco, CA
  • 2013-present
    Associate Professor, Department of Urology, University of California, San Francisco, CA

Honors & Awards

  • 1995
    College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
  • 1996
    American Cancer Society Research Fellowship
  • 1999
    AMA John Conley Ethics Essay Contest, honorable mention
  • 2003
    UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
  • 2004
    UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
  • 2005
    Northern California Urology Resident Research Symposium, 1st place, Clinical Research
  • 2006
    Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
  • 2007
    AUA Gerald P. Murphy Prostate Scholar
  • 2007
    Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
  • 2007
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Society of Urologic Oncology Poster Session, 3rd place overall
  • 2008
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Western Section AUA Poster Session I, 1st place
  • 2017
    2016 physician award, Marin Prostate Cancer Information and Support Group

Selected Publications

  1. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer. J Urol. 2019 Jun 19; 101097JU0000000000000393.
    View on PubMed
  2. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? J Urol. 2019 Jun 19; 101097JU0000000000000392.
    View on PubMed
  3. Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis from CaPSURE. Urology. 2019 May 28.
    View on PubMed
  4. Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing? Clin Genitourin Cancer. 2019 May 24.
    View on PubMed
  5. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 May 23.
    View on PubMed
  6. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 May 23.
    View on PubMed
  7. Nolte AC, Nguyen KA, Perecman A, Katz MS, Kenney PA, Cooperberg MR, Gross CP, Leapman MS. Association Between Twitter Reception at a National Urology Conference and Future Publication Status. Eur Urol Focus. 2019 May 15.
    View on PubMed
  8. Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer. 2019 May 01.
    View on PubMed
  9. Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019 Apr 29.
    View on PubMed
  10. Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer Prostatic Dis. 2019 Apr 29.
    View on PubMed
  11. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance. J Urol. 2019 Apr 26; 101097JU0000000000000290.
    View on PubMed
  12. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 Apr 08; 101097JU0000000000000247.
    View on PubMed
  13. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance of Early Stage Prostate Cancer. J Urol. 2019 Apr 08; 101097JU0000000000000271.
    View on PubMed
  14. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 Jul 15; 104(4):778-789.
    View on PubMed
  15. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 Mar 01; 111(3):301-310.
    View on PubMed
  16. Belair CD, Hu T, Chu B, Freimer JW, Cooperberg MR, Blelloch RH. High-throughput, Efficient, and Unbiased Capture of Small RNAs from Low-input Samples for Sequencing. Sci Rep. 2019 Feb 19; 9(1):2262.
    View on PubMed
  17. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. J Urol. 2019 02; 201(2):300-307.
    View on PubMed
  18. Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar; 30(3):259-269.
    View on PubMed
  19. van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Jan 22.
    View on PubMed
  20. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 Jan 21.
    View on PubMed

Go to UCSF Profiles, powered by CTSI